biotrust glp 1 elevate GLP-1 biotrust glp-1 elevate BioTrust Low
Description
Challenges: The key challenge for Sanofi is competition from more established and better marketed GLP-1 drugs, particularly those from Novo Nordisk and Eli Lilly
Intravenous erythromycin dramatically accelerates gastric emptying in gastroparesis diabeticorum and normals and abolishes the emptying discrimination between solids and liquids
Biological actions and therapeutic potential of the glucagon-like peptides
Gastrointestinal symptoms nausea, diarrhea, constipation are most common, especially early
What about the cost
